重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对医保的预算影响分析

发布时间：2018-02-24 06:47

本文关键词： 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白医疗保险预算　出处：《中国卫生经济》2017年03期 　论文类型：期刊论文

【摘要】：目的:为了对重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(rh TNFR:Fc)对医保预算的影响进行分析。方法:选取IMS Data 2015中的风湿类药品,把药品数量单位换算成限定日剂量(DDD),以IMS Data 2015 rh TNFR:Fc的用量为基线,假设其不同的新增用量比例,按照90%和80%的报销比例分别计算新增的医保支出及其对风湿类药品和全部药品的医保支出的影响。全国医保支出数据来源于政府部门的统计资料。结果:按照90%的报销比例,当rh TNFR:Fc的新增用量为2015年用量的0~100%时,医保支出增加约为5.22~10.43亿元,风湿类药品医保支出增加63.44%~126.87%,全部药品医保支出增加0.04%~0.08%。按照80%的报销比例,其医保支出的增量则相应减少。结论:rh TNFR:Fc进入目录对风湿类药品医保支出的影响较大,但对全部药品医保支出的影响则很小。
[Abstract]:Objective: to analyze the effect of recombinant human tumor necrosis factor receptor-antibody fusion protein rh TNFR: Fcon on health care budget. Methods: rheumatic drugs in IMS Data 2015 were selected. Taking the amount of IMS Data 2015 Rh TNFR:Fc as the baseline, assuming the different proportion of the new dosage, the unit of quantity of drugs is converted into a defined daily dose of DDD. According to the reimbursement ratio of 90% and 80%, respectively, the new health insurance expenditure and its impact on the health insurance expenditure of rheumatic drugs and all drugs are calculated. The national health insurance expenditure data come from the statistics of government departments. Results: according to the 90% reimbursement ratio, When the new dosage of Rh TNFR:Fc is 0 ~ 100 yuan of the amount used in 2015, the medical insurance expenditure increases by 5.22 ~ one billion forty-three million yuan, the medical insurance expenditure of rheumatic drugs increases by 63.44 and 126.87 yuan, and the total medical insurance expenditure increases by 0.04% and 0.08%. According to the reimbursement ratio of 80%, The increment of health insurance expenditure is reduced correspondingly. Conclusion the effect of entering the catalog of TNFR:Fc on the health insurance expenditure of rheumatic drugs is greater, but the effect on the total medical insurance expenditure is very small.
【作者单位】：上海应用技术大学;上海市医学科学技术情报研究所上海市卫生发展研究中心;复旦大学公共卫生学院;
【分类号】：F842.684;R977

【相似文献】